{
    "clinical_study": {
        "@rank": "117502", 
        "arm_group": {
            "arm_group_label": "Pataday", 
            "arm_group_type": "Experimental", 
            "description": "One drop of olopatadine 0.2% once daily in both eyes for 14 days"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to descriptively evaluate the corneal structures of allergic\n      conjunctivitis patients."
        }, 
        "brief_title": "Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Allergic Conjunctivitis", 
        "condition_browse": {
            "mesh_term": [
                "Conjunctivitis", 
                "Conjunctivitis, Allergic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Heidelberg Retina Tomograph (HRT) will be used to descriptively evaluate the corneal\n      structures and assess the immune cell status of allergic conjunctivitis patients pre and\n      post treatment with olopatadine 0.2% in relation to a normative database."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Read, sign, and date an Ethics Committee reviewed and approved informed consent form.\n\n          -  Females of childbearing potential who:\n\n               -  Are not breast-feeding;\n\n               -  Do not intend to become pregnant for the duration of the study;\n\n               -  Are using adequate birth control methods and agree to continue for the duration\n                  of the study.\n\n          -  Able to read, understand and answer questions by investigator.\n\n          -  Willing and able to attend all required study visits and follow directions as\n             stipulated by the protocol and investigator.\n\n          -  History of allergic conjunctivitis (within the past 12 months) and active signs and\n             symptoms of ocular allergies for which treatment is necessary, in the opinion of the\n             investigator.\n\n          -  Visual acuity correctable to 20/30 (Snellen) or better in each eye at distance with\n             or without glasses correction.\n\n          -  Ocular health within normal limits as determined by the investigator.\n\n          -  No contact lens wear 14 days prior to enrollment and willing to not wear contact\n             lenses for the duration of the study.\n\n          -  Willing to follow a 14-day washout period due to contraindicated medication use, if\n             deemed necessary by investigator.\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Contraindications or hypersensitivity to the use of the test article or its\n             components.\n\n          -  Inability or unwillingness to follow all study instructions and complete study visits\n             as required.\n\n          -  Only one sighted eye or visual acuity not correctable to 20/30 (Snellen) in both eyes\n             at the Screening Visit.\n\n          -  Ocular trauma within 6 months prior to Visit 1 in either eye.\n\n          -  Any ocular surgical intervention within six months prior to Visit 1 or anticipation\n             of ocular surgery during the study.\n\n          -  Presumed or actual ocular infection within 30 days prior to Visit 1.\n\n          -  Any severe or serious ocular condition or significant illness.\n\n          -  Any abnormal slit-lamp findings at the time of the Screening Visit.\n\n          -  Contact lens wear within 14 days prior to the study start and unwillingness to\n             undergo a wash-out period of 14 days; unwilling to not wear contact lenses for the\n             duration of the study.\n\n          -  Use of over-the-counter (OTC) ocular medications within the past 14 days unless\n             willing to follow wash out period.\n\n          -  Use of topical or systemic ocular medications requiring longer than a two-week\n             washout period.\n\n          -  Participation in any other investigational study in the 30-day period before entry\n             into this study (i.e., Visit 1) or concomitantly with this study.\n\n          -  Women who are pregnant, nursing, or of childbearing potential not utilizing adequate\n             birth control measures.\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "17", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697969", 
            "org_study_id": "M-12-047"
        }, 
        "intervention": {
            "arm_group_label": "Pataday", 
            "description": "One drop once daily in both eyes for 14 days", 
            "intervention_name": "Olopatadine hydrochloride ophthalmic solution, 0.2%", 
            "intervention_type": "Drug", 
            "other_name": "PATADAY\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": "Olopatadine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "allergic conjunctivitis", 
            "Pataday", 
            "Olopatadine"
        ], 
        "lastchanged_date": "July 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Iowa City", 
                    "country": "United States", 
                    "state": "Iowa", 
                    "zip": "52242-1091"
                }, 
                "name": "University of Iowa"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2%", 
        "overall_official": [
            {
                "affiliation": "University of Iowa", 
                "last_name": "Christine Sindt, OD, FAAO", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Alcon Research", 
                "last_name": "Pam Kaur, MS PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "As rated by the patient on a 0-4 scale.", 
                "measure": "Patient-Assessed Ocular Itching", 
                "safety_issue": "No", 
                "time_frame": "Day 1"
            }, 
            {
                "description": "As rated by the patient on a 0-4 scale.", 
                "measure": "Patient-Assessed Ocular Itching", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697969"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}